Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 01/07/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 938 publications
INDIVIDUAL ARTICLE: The Utility of Delgocitinib in Chronic Hand Eczema.
Journal: Journal of drugs in dermatology : JDD
Published: October 02, 2025
Comparative Efficacy of Monotherapies for Chronic Hand Eczema: A Network Meta-Analysis Study.
Journal: Journal of cosmetic dermatology
Published: August 20, 2025
Potential role of COUP-TF in regulating major yolk protein gene expression in sea urchin.
Journal: General and comparative endocrinology
Published: July 31, 2025
Physician-Reported Treatment Patterns in Moderate to Severe Chronic Hand Eczema: the RWEAL Multinational Medical Chart Review.
Journal: Dermatology and therapy
Published: July 15, 2025
High-value utilization of brewers' spent grain in extruded corn-based foods: physicochemical, functional, and metabolomic insights.
Journal: Food chemistry: X
Published: July 14, 2025
Exploring the Varied Clinical Presentation of Pediatric Asthma through the Metabolome.
Journal: American journal of respiratory and critical care medicine
Published: February 18, 2025
Alitretinoin is not a suitable treatment for the majority of chronic hand eczema patients.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: December 02, 2024
The Efficacy and Safety of Non-Biologic and Biologic Treatments in Palmoplantar Pustular Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis.
Journal: The Australasian journal of dermatology
Published: October 21, 2024
Alitretinoin versus phototherapy as the first-line treatment in adults with severe chronic hand eczema: the ALPHA RCT.
Journal: Health technology assessment (Winchester, England)
Published: October 04, 2024
Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial.
Journal: Lancet (London, England)
Published: September 26, 2024
Last Updated: 01/07/2026